The metabolic syndrome in women

Women's Health

Volumn 2, Issue 6, 2006, Pages 889-898

  Rosano, Giuseppe M C ^a   Vitale, Cristiana ^a   Mercuro, Giuseppe ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cardiovascular risk; Estradiol; Hormone replacement therapy; Menopause; Prognosis; Therapy

Indexed keywords

ACARBOSE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; DROSPIRENONE; ESTROGEN; GESTAGEN; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; DRUG MIXTURE; DRUG RECEPTOR BINDING; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FLUID RETENTION; GLUCOSE METABOLISM; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SYMPATHETIC TONE; WEIGHT REDUCTION; WOMEN'S HEALTH;

EID: 33751426215     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.6.889     Document Type: Review

References (56)

1. Rosano GM, Fini M: Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy, Cardiol. Rev. 10(1), 51-60 (2002).
2. Avogaro P, Crepaldi G, Enzi G, Tiengo A: Metabolic aspect of essential obesity. Epatologia 11(3), 226-238 (1965).
3. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
4. Reaven GM: Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44, 121-131 (1993).
5. Reaven G: Syndrome X: 10 years after. Drugs 58(Suppl. 1), 19-20 (1999).
6. Grundy SM, Cleeman JI, Daniels SR et al.: American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/Nationai Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005).
7. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 163, 427-436 (2003).
8. Essah PA, Nestler JE: The metabolic syndrome in polycystic ovary syndrome. J. Endocrinol. Invest. 29(3), 270-280 (2006).
9. Carr MC: The emergence of the Metabolic Syndrome with menopause. J. Clin. Endocrinol. Metab. 88(6), 2404-2411 (2003).
10. Tchernof A, Poehlman ET, Despres JP: Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab. 26(1), 12-20 (2000).
11. Gambacciani M, Ciapponi M, Cappagli B, Canussi B, De Simone L, Genazzani AR: Climacteric modifications in body weight and fat tissue distribution. Climacteric 2(1), 37-44 (1999).
12. Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M: Regional obesity and risk of cardiovascular disease; the Framingham Study. J. Clin. Epidemiol. 44(2), 183-190 (1991).
13. Carr DB, Utzschneider KM, Hull RL et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53(8). 2087-2094 (2004).
14. Yusuf S. Hawken S, Ounpuu S et al.: INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366(9497), 1640-1649 (2005).
15. Poehlman ET, Toth MJ, Gardner AW: Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann. Intern. Med. 123(9), 673-675 (1995.).
16. Chmoulioivsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A: Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas 32(3), 147-153 (1999).
17. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR: Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 39(2), 125-132 (2001).
18. Rexrode KM, Carey VJ, Hennekens CH et al.: Abdominal adiposity and coronary heart disease in women. JAMA 280(21), 1843-1848 (1998).
19. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162(16), 1867-1872 (2002).
20. Harris MM, Stevens J, Thomas N, Schreiner P, Folsom AR: Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes. Res. 8(7), 516-524 (2000).
21. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC: The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur. J. Clin. Invest. 23(8), 466-473 (1993).
22. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA: A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil. Steril. 60(4), 664-647 (1993).
23. Espeland MA, Hogan PE, Fineberg SE et al.: Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 21(10), 1589-1595 (1998).
24. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K, DECODE Insulin Study Group: Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47(7), 1245-1256 (2004).
25. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S. Yki-Jarvinen H: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30(5), 1144-1149 (1997).
26. Assmann G, Schulte H: The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur. J. Epidemiol. 8(Suppl. 1), 99-103 (1992).
27. de Aloysio, D, Gambacciani M, Meschia M et al.: The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 147, 147-153 (1999).
28. Jensen J, Nilas L, Christiansen C: Influence of menopause on serum lipids and lipoproteins. Maturitas 12, 321-331 (1990).
29. Pansini F, Bonaccorsi G, Campobasso C et al.: Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas 17, 181-190 (1993).
30. Alexandersen P, Haarbo J. Sandholdt I, Shalmi M, Lawaetz H, Christiansen C: Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: a secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 18(6), 902-907 (1998).
31. Shlipak MG, Simon JA, Vittinghoff E et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283, 1845-1852 (2000).
32. Bruschi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG: Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet. Gynecol. 88, 950-954 (1996).
33. Rosano GM, Patrizi R, Leonardo F et al.: Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am. J. Cardiol. 80(6), 815-817 (1997).
34. Mercuro G, Podda A, Pitzalis L et al.: Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am. J. Cardiol. 85(6), 787-789, A9 (2000).
35. Masuo K, Mikami H, Ogihara T, Tuck ML: Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am. J. Hypertens. 10(l), 77-83 (1997).
36. Sjoberg L, Kaaja R, Tuomilehto J: Epidemiology of postmenopausal hypertension. Int. J. Clin. Pract. 139(Suppl.). 4-12 (2004).
37. Wong ND, Thakral G, Franklin SS et al.: Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am. Heart J. 145(5), 888-895 (2003).
38. Sclavo M: Cardiovascular risk factors and prevention in women: similarities and differences. Ital. Heart J. 2(Suppl. 2), 125-141 (2001).
39. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB: Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 159, 1104-1109 (1999).
40. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am. J. Cardiol. 91(12), 1421-1426 (2003).
41. Tuomilehto J, Lindstrom J, Eriksson JG et al., Finnish Diabetes Prevention Study Group: Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001).
42. Tuomilehto J: Cardiovascular risk: prevention and treatment of the metabolic syndrome. Diabetes Res. Clin. Pract. 68(Suppl. 2), S28-S35 (2005).
43. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA: A systematic review of drug therapy to delay or prevent Type 2 diabetes. Diabetes Care 28(3), 736-744 (2005).
44. Abuissa H, Bel DS, O'Keefe JH Jr: Strategies to prevent Type 2 Diabetes. Curr. Med. Res. Opin. 21(7), 1107-1114 (2005).
45. Vitale C, Mercuro G, Cornoldi A et al.: Metformin improves endothelial function in patients with metabolic syndrome. J. Int. Med. 258(3), 250-256 (2005).
46. Practice Guidelines for Primary Care Physicians: ESH/ESC Hypertension Guidelines. J. Hypertens. 21(10), 1779-1786 (2003).
47. Scheen AJ: Renin-Angiotensin system inhibition prevention prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 30(6), 498-505 (2004).
48. Sever PS, Poulter NR, Dahlof B et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care 28(5), 1151-1157 (2005).
49. Uchida K, Azukizawa S, Kigoshi T et al.: Effect of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance. Clin. Ther. 16(3), 466-470 (1994).
50. Vitale C, Mercuro G, Castiglioni C et al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 4, 6 (2005).
51. Chrysant SG: The ALLHAT study: results and clinical implications. QJM 96(10), 771-773 (2003).
52. Haenni A, Lithell H: Moxonidine improves insulin sensitivity in insuiln-resistant hypertensives. J. Hypertens. 17(Suppl. 3), S29-S35 (1999).
53. Kirch K, Hutt HJ, Planitz V: Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J. Clin. Pharmacol. 30(12), 1088-1095 (1990).
54. Mc Donough PG: The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. Fertil. Steril. 78(5), 951-956 (2002).
55. Koh KK, Sakuma I: Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscl. Thromb. Vasc. Biol. 24(7), 1171-1179 (2004).
56. Rubig A: Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 6(Suppl. 3), 49-54 (2003).